证券日报网讯 11月6日晚间，海正药业发布公告称，近日，公司控股子公司浙江海正动物保健品有限公 司收到中华人民共和国农业农村部核准签发的复方制霉菌素软膏、托曲珠利混悬液兽药产品批准文号批 件。 （文章来源：证券日报） ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Product Approval - The approved products include Compound Streptomycin Ointment, which is used to treat otitis externa in dogs and cats caused by bacteria sensitive to neomycin, fungi sensitive to streptomycin, and ear mites sensitive to chlorpyrifos [1] - The second product, Tocilizumab Suspension, is intended for the prevention of coccidiosis in piglets and calves [1] Strategic Implications - The approval of these veterinary drug products will enrich the company's veterinary medicine product line and structure, facilitating its strategic layout in the veterinary drug sector [1] - This development is expected to enhance the company's market competitiveness within the veterinary medicine industry [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Group 1 - The company’s subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has been granted approval for the compound streptomycin ointment and torquatozole suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure, supporting its strategic layout in the veterinary medicine sector [1] - This development is expected to improve the company's market competitiveness in the veterinary drug market [1]

Core Viewpoint - Haizheng Pharmaceutical announced that its subsidiary, Haizheng Animal Health, received approval from the Ministry of Agriculture and Rural Affairs for two veterinary drug products, which will enhance the company's product line in animal medicine [1] Group 1: Product Approvals - The approved products include Compound Streptomycin Ointment, valid from September 5, 2025, to September 4, 2030, for treating external ear infections in dogs and cats [1] - The second product, Tocilizumab Suspension, is approved for use from October 24, 2025, to October 23, 2030, aimed at preventing coccidiosis in piglets and calves [1] Group 2: Market Impact - The approval of these products will enrich the company's veterinary drug portfolio, although the market launch and sales are subject to uncertainties related to policies and market conditions [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its veterinary drug products, which will enhance its product line and market competitiveness in the veterinary sector [1] Group 1 - Haizheng Pharmaceutical's subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has obtained approval for the compound griseofulvin ointment and torasemide suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure [1] - This development is expected to further promote the company's strategic layout in the veterinary drug sector [1]